Liver Disease Clinical Trials in Philadelphia

Showing 61-79 of 79 trials

The Patient-Reported Outcomes Project of HCV-TARGET

NCT02601820

The PROP UP research study is funded by The Patient Centered Outcomes Research Institute (PCORI). PROP UP is a multi-centered prospective observational study that will evaluate all-oral treatment regimens for chronic hepatitis C viral (HCV) infection regarding several patient-reported outcomes (PROs) such as HCV-associated symptoms, treatment side effects, medication adherence, out of pocket costs, comorbid conditions, and long-term benefits of cure and harms of treatment to compare PROs of different treatment regimens, treatment durations, and patient subgroups. Participants will be recruited from 9 U.S. liver centers. Approximately 1920 patients with HCV infection who are prescribed a regimen containing Sofosbuvir/Ledipasvir(SOF/LED), SOF/Velpatasvir(SOF/VEL), Grazoprevir/Elbasvir(GRZ/ELB), OBV/PTV/r + DSV (PRoD), or daclatasvir/SOF (DAC/SOF) will be recruited and approximately 1600 patients who are approved and begin HCV treatment will be enrolled in the longitudinal study. PRO surveys will be evaluated before, during and after HCV treatment. PROP UP is a collaborative effort between behavioral and biomedical researchers, a patient engagement group and a patient advocacy organization.

Hepatitis C, ChronicLiver Diseases

University of North Carolina, Chapel Hill1,601 participantsStarted Nov 2015

Davis, California, United States • New Haven, Connecticut, United States • Gainesville, Florida, United States +8 more locations

COMPLETEDPhase 4< 1 mile

The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy

NCT01842581

The purpose of the study is to evaluate if rifaximin alone or rifaximin plus lactulose delays the onset of hepatic encephalopathy (HE) in participants with cirrhosis who have had a previous episode of HE.

Hepatic EncephalopathyCirrhosis

Bausch Health Americas, Inc.222 participantsStarted Jan 2013

Phoenix, Arizona, United States • Coronado, California, United States • Fresno, California, United States +40 more locations

The Patient-Reported Outcomes Project of HCV-TARGET

The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy

Liver Disease Trials in Other Cities

Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis

Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure

Adult-to-Adult Living Donor Liver Transplantation Study

Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation

Mycophenolate Mofetil Immunosuppression Without/With Reduced Dose Calcineurin Inhibitor Long After Liver Transplantation

Epidemiological Study in Children and Adolescents With Chronic Hepatitis B

Phase I Trial of Silymarin for Chronic Liver Diseases

Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver

Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Cirrhotic Ascites Treatment With Satavaptan in Patients With Ascites Due to Cirrhosis of the Liver (CATS)

Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis

An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis

Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study

A2ALL-Patients Safety System Improvements in Living Donor Liver Transplantation

Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF

Tesamorelin Effects on Liver Fat and Histology in HIV

Study of Combivir for Patients With Primary Biliary Cirrhosis

Other Conditions in Philadelphia